NEW YORK – MedMira said Tuesday that it has received Health Canada approval for point-of-care use of its Reveal Rapid G4 HIV-1/2 Test.
The test detects HIV-1/2 antibodies in finger prick samples and is intended for use by healthcare professionals in any healthcare setting, the company said.
According to Halifax, Nova Scotia-based MedMira, the Reveal HIV test has sensitivity of 99.6 percent and specificity of 99.7 percent.
"As the rates of HIV infections continue to rise in Canada, healthcare providers need diagnostics that are not only accurate but also simple, cost-effective, and accessible in any setting," MedMira CEO Hermes Chan said in a statement. "Whether in underserved remote areas or urban centers facing overburdened healthcare systems, our test is designed to provide immediate and actionable results."
The approval follows the December approval by Health Canada of MedMira's Multiplo Rapid TP/HIV Test for the detection of HIV-1/2 and syphilis. The company said it anticipates the approval of its standalone syphilis test, the Reveal TP, in coming weeks.